Subtype
Invasive Renal Pelvis and Ureter Urothelial Carcinoma
CI-CAN-00005632Explore in graph →
2 active trials
- NCIt
- C39879
Loading cancer entity…
Subtype
CI-CAN-00005632Explore in graph →
Clinical trials
3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT04871529 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | terminated | Phase 2 | 6 | SWOG Cancer Research Network |
| 1 |
| Dec 30, 2024 |
| clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials